Stability Assessment for Bioanalytical Assays

Stability studies are an essential component of bioanalytical assay validation, ensuring that the analyte remains stable in the sample matrix under various storage and handling conditions. These studies assess the analyte's stability over time to ensure that assay results are accurate and reliable throughout the sample collection, processing, and analysis process. Here's how stability studies are typically performed and evaluated:

Stability Study Design: Determine the stability parameters you want to assess, such as short-term stability, long-term stability, freeze-thaw stability, and stability under various storage conditions.

Prepare Spiked Samples: Prepare a set of spiked samples containing the analyte at different concentration levels, representative of the samples being analyzed.

Stability Conditions: Define the specific stability conditions to evaluate, which may include:

Short-Term Stability: Analyze samples immediately after preparation to assess stability over a short period (e.g., hours).

Long-Term Stability: Store samples at relevant temperatures over an extended period (e.g., weeks to months) to assess stability under ambient, refrigerated, and frozen conditions.

Freeze-Thaw Stability: Subject samples to multiple freeze-thaw cycles to assess stability after repeated freezing and thawing.

Analysis: At defined time points, analyze the stability samples using the same bioanalytical assay used for routine sample analysis. Analyze stability samples in triplicate or as per experimental design.

Calculation: Calculate the analyte's concentration for each stability sample and time point.

Data Analysis: Evaluate the data to determine whether the analyte's concentration remains consistent across different time points and stability conditions. Calculate the percent change in concentration compared to the initial concentration.

Acceptance Criteria: Set predefined acceptance criteria for each stability parameter based on regulatory guidelines or internal standards. These criteria determine the allowable change in concentration for the analyte to be considered stable.

Interpretation: Interpret the results to assess the analyte's stability under various conditions. If the analyte remains within the defined acceptance criteria, it is considered stable. If significant changes in concentration are observed, further investigation or corrective actions may be necessary.

Documentation: Thoroughly document the stability study design, procedures, results, calculations, and any actions taken in response to the findings. This documentation provides a comprehensive record of the stability assessment.

Reporting: Incorporate the stability study results into the overall assay validation report. Summarize the findings and conclusions related to the analyte's stability under different conditions.

Stability studies ensure that bioanalytical assay results are reliable and representative of the actual analyte concentrations in the samples. By assessing stability, researchers can determine appropriate sample handling, storage, and analysis procedures to maintain the integrity of the analyte throughout the testing process.

Human Genome Editing: FDA Draft Guidance Summary

Consideration for Developing Gene Editing Product 1. Genome Editing Methods: Genome editing can be achieved through nuclease-dependent or nuclease-independent methods. Nuclease-dependent methods involve introducing site-specific breaks in DNA using technologies like zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), modified-homing endonucleases, and CRISPR-associated (Cas) nucleases. These breaks can lead to modification of the DNA sequence at the cleavage site. Nuclease-independent methods can change DNA sequences without cleaving the DNA and include techniques like base editing and synthetic triplex-forming peptide nucleic acids. The choice of GE technology should consider factors such as the mechanism of action, the ability to target specific DNA sequences, and the potential to optimize components for efficiency, specificity, or stability. 2. Type and Degree of Genomic Modification: Different GE approaches rely on DNA repair pathways such as ho

Human Gene Therapy for Neurodegenerative Diseases: FDA Guidance Summary

Neurodegenerative diseases are a diverse group of disorders characterized by the progressive degeneration of the central or peripheral nervous system, and they can have various causes and clinical characteristics. This guidance document is a resource for sponsors on different aspects of product development, preclinical testing, and clinical trial design. It acknowledges the unique challenges and considerations associated with developing GT products for such complex and varied diseases. Below are the key summaries from the guidance. CONSIDERATIONS FOR CHEMISTRY, MANUFACTURING AND CONTROLS (CMC) The considerations for Chemistry, Manufacturing, and Controls (CMC) when developing gene therapy (GT) products for the treatment of neurodegenerative diseases are crucial for ensuring the safety and efficacy of these advanced therapies. Here, we will elaborate on the specific CMC considerations outlined in your text: Route of Administration and Product Volume: Neurodegenerative diseases often r

Cellular & Gene Therapy Guidances (Food and Drug Administration)

Studying Multiple Versions of a Cellular or Gene Therapy Product in an Early-Phase Clinical Trial; Draft Guidance for Industry 11/2022 Human Gene Therapy for Neurodegenerative Diseases; Guidance for Industry 10/2022 Considerations for the Development of Chimeric Antigen Receptor (CAR) T Cell Products; Draft Guidance for Industry 3/2022 Human Gene Therapy Products Incorporating Human Genome Editing; Draft Guidance for Industry 3/2022 Interpreting Sameness of Gene Therapy Products Under the Orphan Drug Regulations; Guidance for Industry 9/2021 Manufacturing Considerations for Licensed and Investigational Cellular and Gene Therapy Products During COVID-19 Public Health Emergency; Guidance for Industry 1/2021 Chemistry, Manufacturing, and Control (CMC) Information for Human Gene Therapy Investigational New Drug Applications (INDs); Guidance for Industry 1/2020 Long Term Follow-up After Administration of Human Gene Therapy Products; Guidance for Industry 1/2020 Testing of Retroviral Vecto

Stem loop RT-PCR for Detection of siRNA in Animal Tissues

Step Loop RT-PCR for Detection of Small Interfering RNA (siRNA) The recent publications described a novel used the novel method for the detection of siRNAs using a TaqMan®-based approach. This approach utilizes similar strategy that has been used for microRNA detection. The approach is illustrated in below. In brief, the RT step occurs in the presence of a stem-loop RT primer that is complementary to the last 6–10 bases of the 3′ end of the antisense strand of the target siRNA. The stem-loop primer contains an additional universal sequence at the 5′ end that facilitates a TaqMan-based detection strategy in the subsequent qPCR step. As in the case of microRNA, the forward primer for qPCR is sequence-specific for the target siRNA. For sequence compositions that yield a low predicted melting temperature (Tm), the forward primer is designed as a tailed primer to help increase Tm. Stem Loop PCR for SiRNA Detection Step 1: Preparation of liver and plasma samples for the quantification of si

Engineering AAV vectors for enhanced safety profiles

Engineering AAV vectors for enhanced safety profiles involves multiple strategies at both the vector genome and capsid levels. Here is a breakdown of these strategies: Vector Genome Level: Modifying Vector Genome Sequences: Scientists modify AAV vector genomes by adding, mutating, or deleting specific sequences. For example, self-complementary AAV (scAAV) vectors are designed by deleting key signals from the second inverted terminal repeat (ITR), allowing for more efficient genome replication. Codon Optimization: Optimizing the codon usage of the transgene can enhance its expression efficiency. Promoter and PolyA Sequence Selection: Careful selection and manipulation of promoter and polyadenylation (polyA) sequences can influence transgene expression and tissue specificity. Capsid Engineering: Capsid engineering strategies can be categorized into four main categories: Directed Evolution: This approach involves creating capsid mutant libraries using error-prone PCR or introducing pepti

Cell And Gene Therapy: Research, Development & Regulatory Guidance

Search This Blog